Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Mymetics
Mymetics
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines
Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development
Mymetics to advance development of virosome-based malaria vaccine candidate
In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development
Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute
Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development
Astellas forms partnership with ClearPath to build vaccine portfolio
In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
Research & Development
Mymetics announces change of directors and management
Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates
Pharmaceutical
Mymetics makes two appointments
New president and ceo and chairman
Subscribe now